Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

BACKGROUND: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffecti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Fumet, Jean-David, Isambert, Nicolas, Hervieu, Alice, Zanetta, Sylvie, Guion, Jean-Florian, Hennequin, Audrey, Rederstorff, Emilie, Bertaut, Aurélie, Ghiringhelli, Francois
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012564/
https://ncbi.nlm.nih.gov/pubmed/29942666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados